Fabrus LLC, La Jolla, California, USA.
Nat Biotechnol. 2010 Nov;28(11):1195-202. doi: 10.1038/nbt.1694. Epub 2010 Oct 24.
Antibody discovery typically uses hybridoma- or display-based selection approaches, which lack the advantages of directly screening spatially addressed compound libraries as in small-molecule discovery. Here we apply the latter strategy to antibody discovery, using a library of ∼10,000 human germline antibody Fabs created by de novo DNA synthesis and automated protein expression and purification. In multiplexed screening assays, we obtained specific hits against seven of nine antigens. Using sequence-activity relationships and iterative mutagenesis, we optimized the binding affinities of two hits to the low nanomolar range. The matured Fabs showed full and partial antagonism activities in cell-based assays. Thus, protein drug leads can be discovered using surprisingly small libraries of proteins with known sequences, questioning the requirement for billions of members in an antibody discovery library. This methodology also provides sequence, expression and specificity information at the first step of the discovery process, and could enable novel antibody discovery in functional screens.
抗体发现通常使用杂交瘤或展示为基础的选择方法,这些方法缺乏直接筛选空间寻址化合物库的优势,就像小分子发现一样。在这里,我们应用后者的策略来进行抗体发现,使用了一个由从头 DNA 合成和自动化蛋白质表达和纯化产生的约 10000 个人类种系抗体 Fab 的文库。在多重筛选测定中,我们获得了针对九个抗原中的七个的特异性命中。使用序列-活性关系和迭代诱变,我们将两个命中的结合亲和力优化到低纳摩尔范围。成熟的 Fab 在基于细胞的测定中显示出完全和部分拮抗活性。因此,使用具有已知序列的蛋白质的小文库就可以发现蛋白质药物先导物,这对抗体发现文库中需要数十亿个成员的要求提出了质疑。该方法还在发现过程的第一步提供了序列、表达和特异性信息,并且可以在功能筛选中实现新型抗体发现。